Greenwich LifeSciences (GLSI) Total Non-Current Liabilities (2024 - 2025)
Greenwich LifeSciences (GLSI) posted Total Non-Current Liabilities of $5.2 million for Q4 2025, up 132.6% on a QoQ basis from $2.2 million in Q2 2025, and up 78.92% year-over-year from $2.9 million in Q4 2024.
Greenwich LifeSciences (GLSI) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
Greenwich LifeSciences' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $5.2 million for Q4 2025.
- Quarterly Total Non-Current Liabilities rose 78.92% year-over-year to $5.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.2 million (up 78.92% YoY) and the FY2025 annual result came in at $5.2 million, up 78.92% from the prior year.
- Total Non-Current Liabilities was $5.2 million for Q4 2025 at Greenwich LifeSciences, up from $2.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.2 million in Q4 2025 and bottomed at $2.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | 5.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.15 Mn |
| Jun 30, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.24 Mn |
| Dec 31, 2024 | 2.88 Mn |